Johnson & Johnson $JNJ Shares Bought by Czech National Bank

Czech National Bank grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 611,668 shares of the company’s stock after buying an additional 23,539 shares during the period. Johnson & Johnson accounts for approximately 0.8% of Czech National Bank’s holdings, making the stock its 19th biggest holding. Czech National Bank’s holdings in Johnson & Johnson were worth $113,415,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Brighton Jones LLC increased its position in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares in the last quarter. United Bank grew its stake in Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after buying an additional 4,876 shares during the period. Versor Investments LP acquired a new stake in shares of Johnson & Johnson in the first quarter worth $444,000. T. Rowe Price Investment Management Inc. acquired a new position in shares of Johnson & Johnson during the 1st quarter valued at $102,460,000. Finally, PGIM Custom Harvest LLC boosted its position in Johnson & Johnson by 11.2% during the 1st quarter. PGIM Custom Harvest LLC now owns 1,761 shares of the company’s stock worth $292,000 after purchasing an additional 177 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Scotiabank began coverage on Johnson & Johnson in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 price objective on the stock. Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price on the stock in a report on Monday, October 20th. BMO Capital Markets restated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Finally, Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $210.25.

Johnson & Johnson Price Performance

JNJ stock opened at $208.23 on Friday. The stock’s 50 day moving average is $197.78 and its two-hundred day moving average is $178.67. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $215.18. The company has a market capitalization of $501.68 billion, a PE ratio of 20.10, a P/E/G ratio of 2.28 and a beta of 0.36. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.